Scancell has widened its H1 pretax loss to £3.0m, from a year-ago loss of £2.8m.
CEO John Chiplin commented:
"We have continued to make significant progress in the period, both in terms of the maturing clinical data with SCIB1 and further scientific developments on both the ImmunoBody and Moditope platforms.
"We now have a pipeline of three products across five cancer indications and clinical success with any one of these products could transform the value of the business.
"The Board believes that further clinical studies could add significant value to the Company and is continuing to explore a number of funding options to ensure that the Company has the resources to progress these programmes further.
"Scancell has arrived at an exciting point in its development. We now have the opportunity to transform the business from a small UK-based and largely scientifically-based enterprise into an international force in immuno-oncology.
"We remain committed to driving this process forward in the US and elsewhere, and to realising the value that has been accumulating over recent years, both for the benefit of our shareholders and cancer patients."